Navigation Links
La Jolla Institute identifies new therapeutic target for asthma, COPD and other lung disorders
Date:4/17/2011

annually in U.S. health care costs. COPD is one of the most common lung diseases and comes in two main forms, chronic bronchitis and emphysema. More than 12 million Americans have been diagnosed with COPD, which is a major cause of disability and the fourth leading cause of death in the United States.

Current therapies for asthma and COPD primarily include corticosteroids, bronchodilators, and leukotriene antagonists, but these are thought to have little impact, if any, on airway remodeling, said Dr. Croft.

Dr. Croft said emerging data on the role of the tumor necrosis factor (TNF) super family of molecules in fueling inflammatory diseases, including his own finding on OX40 Ligand and its receptor's action in triggering inflammation in asthma, prompted him to take a close look at fellow TNF molecule, LIGHT. "We hypothesized that LIGHT might be involved in driving aspects of lung inflammation or have a role in lung dysfunction that was different than our previous findings on OX40L," he said. "As we were undertaking our studies, a report found that increased sputum LIGHT levels in people with asthma correlated with decreased lung function, which was in line with our thinking."

Using two mouse models of chronic asthma and a therapeutic blocking strategy, Dr. Croft said he and his team "demonstrated a direct role for LIGHT in promoting and controlling the extent of remodeling in the lung."

In a related finding, published March 14 in the Journal of Experimental Medicine, Dr. Croft also showed a connection between LIGHT and T cell-fueled inflammation that contributes to other aspects of asthmatic disease. "We showed that blocking LIGHT binding to one of its receptors, named the herpesvirus entry mediator, reduced the ability of T lymphocytes, induced with a model allergen, to survive long-term. This strongly curtailed lung inflammation associated with asthma when the allergen was subsequently inhaled," he said. The findings we
'/>"/>

Contact: Bonnie Ward
contact@liai.org
619-303-3160
La Jolla Institute for Allergy and Immunology
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. La Jolla Institute-led team illuminates cell pathway key to insulin resistance in Type 2 diabetes
2. La Jolla Institute validates Type 1 diabetes computer models predictive success through lab testing
3. La Jolla Institute scientist Klaus Ley receives Malpighi award
4. La Jolla Institute scientist leads team which discovers important new player in diabetes onset
5. Visionary concept earns La Jolla Institute scientist prestigious NIH Pioneer Award
6. La Jolla Institute discovers novel tumor suppressor
7. La Jolla Institute signs exclusive license agreement with Medimmune on major asthma discovery
8. Allen Institute for Brain Science announces first comprehensive gene map of the human brain
9. NYU Cancer Institute experts present at the AACR 102nd Annual Meeting 2011
10. Brigham and Womens Hospital researcher named National Space Biomedical Research Institute Fellow
11. Challenges for biofuels: New life cycle assessment report from Energy Biosciences Institute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... focused on the growing mobile commerce market, announced ... for BEHAVIORAL-DIRECTED AUTHENTIATION METHOD AND SYSTEM. ... secure method to make payments.  With this patent, ... with its groundbreaking voice-direct payment patent application, with ...
(Date:7/8/2015)... 2015 Summary Pancreatic cancer is the ... fatal, with a mortality rate of 10.9 deaths per ... cancer patients has highlighted a significant need for new ... met by the current market. A highly active ... varying molecule types and mechanisms of action, which provides ...
(Date:7/7/2015)... VIEW, Calif. , July 7, 2015 /PRNewswire/ ... biometrics market, Frost & Sullivan recognizes Credence ID, ... Sullivan Entrepreneurial Company of the Year Award. ... suite to aid in its mission of offering ... under-recognized populations globally. As Credence ID was formed ...
Breaking Biology News(10 mins):NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5
... pollution most often produced from biomass burning, cooking with ... in the atmosphere three to four times greater than ... article in the journal Nature Geoscience. Scripps Institution ... Ramanathan and University of Iowa chemical engineer Greg Carmichael, ...
... REST blocks the expression of a microRNA that prevents ... to differentiate into specific cell types, scientists at The ... in the journal Nature. Researchers show RE1-silencing ... stem cells, said senior author Sadhan Majumder, Ph.D., professor ...
... may cluster the genes needed to make defence chemicals. Their ... products of use as drugs, herbicides or crop protectants. Using ... as a template, they uncovered a previously unknown gene cluster ... now want to extend the search to other plants. ...
Cached Biology News:Black carbon pollution emerges as major player in global warming 2Black carbon pollution emerges as major player in global warming 3Protein protects embryonic stem cells' versatility and self-renewal 2Protein protects embryonic stem cells' versatility and self-renewal 3Plant gene clusters for natural products 2
(Date:7/30/2015)... ... , ... The 2015 Market Research Report on the Global Propanol Industry ... Propanol market with a focus on the Chinese situation. Major companies included in the ... Chemical, Sanofi, Royal Dutch Shell, LG Chem and Zhejiang Xinhua Chemical. , The report ...
(Date:7/30/2015)... 2015   Senomyx , Inc. (NASDAQ: SNMX ... to discover, develop, and commercialize novel flavor ingredients for ... financial results for the second quarter 2015. ... remain on track to achieve our commercial and financial ... of the Company. "Since our last quarterly earnings report, ...
(Date:7/30/2015)... Pa. , July 30, 2015  Discovery ... that it has received the second $1.0M tranche ... Innovation Research (SBIR) grant valued at up to ... company,s aerosolized KL4 surfactant as a potential medical ... injury.  Discovery Labs was awarded an initial $1.0 ...
(Date:7/29/2015)... July 30, 2015 Sanofi, ... publie ses résultats pour le premier semestre 2015. ... les résultats. Visionner l,interview vidéo et ... Au sommaire de l,interview :  ... Moteurs de croissance - Diabète ...
Breaking Biology Technology:Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3
... CALUIRE, France, Feb. 19 Setaram,Inc., a ... announces the acquisition of Hy-Energy LLC (Newark, ... scientific instruments for,the ever-expanding field of clean ... a full suite of analytical capabilities which,complement ...
... 19 Barr Pharmaceuticals,Inc. (NYSE: BRL ) ... received final approval from the U.S. Food and ... Ingelheim,Pharmaceuticals, Inc.,s Mirapex(R) Tablets (Pramipexole Dihydrochloride),0.125mg, 0.25mg, 0.5mg, ... is the,first to file an Abbreviated New Drug ...
... Technology Providers Broadens ... Opportunities for Distribution, New Markets, SILVER SPRING ... and Immersion Medical, a subsidiary of Immersion Corporation,announced ... enhanced version of B-Line Medical,s SimCapture(TM) product. SimCapture,is ...
Cached Biology Technology:Setaram Inc. Acquires Hy-Energy LLC 2Barr Receives Final Approval for Generic Mirapex(R) Tablets, 0.125mg, 0.25mg, 0.5mg, 1mg & 1.5mg 2Barr Receives Final Approval for Generic Mirapex(R) Tablets, 0.125mg, 0.25mg, 0.5mg, 1mg & 1.5mg 3Barr Receives Final Approval for Generic Mirapex(R) Tablets, 0.125mg, 0.25mg, 0.5mg, 1mg & 1.5mg 4B-Line Medical and Immersion Medical Announce Partnership 2B-Line Medical and Immersion Medical Announce Partnership 3
Anti-Human Factor XIII HRPO (Polyclonal) (sheep IgG)...
Recognizes the 41 and 43 kDa G-proteins present in liver plasma membranes and Gq/11alpha expressed in the Sf9 insect cell expression system. Negative for recombinant G(I)alpha subtypes....
Rabbit polyclonal to Flagellin ( Abpromise for all tested applications). Antigen: Synthetic peptide from the flagellin C terminal domain of Burkholderia pseudomallei....
This application changes sensitive keywords in an FCS file to remove patient information. It was contributed by Dr. David Miller....
Biology Products: